This study investigated the safety and efficacy of the sodium-glucose co-transporter-2 (SGLT2) inhibitor luseogliflozin with differing carbohydrate intakes in Japanese individuals with type 2 diabetes (T2D). Participants were randomly assigned to 3 carbohydrate-adjusted meals for 14 days (days 1-14; a high carbohydrate [HC; 55% total energy carbohydrate] and high glycae- at all time points. Ketone bodies on day 15 were significantly higher in the LC-HGI group compared with the HC-HGI and HC-LGI groups. In conclusion, luseogliflozin has similar efficacy and safety in Japanese people with T2D when meals contain 40% to 55% total energy carbohydrate, but a strict LC diet on this class of drug should be avoided to prevent SGLT2 inhibitor-associated diabetic ketoacidosis.
| INTRODUCTION
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have recently been developed as a novel class of glucose-lowering agents for the management of type 2 diabetes (T2D).
1,2 SGLT2 inhibitors enhance urinary glucose excretion (UGE), thereby ameliorating both pre-and postprandial glucose excursions insulin-independently, and also lead to substantial body weight reduction. Clinical trials have demonstrated the efficacy and safety of SGLT2 inhibitors, as a class, in people with T2D; however, there are concerns regarding severe adverse events associated with the use of SGLT2 inhibitors in real clinical settings. 3 Among these, diabetic ketoacidosis (DKA) near
| Study population
Eligible participants were aged 20 to 64 years, had a treatment history of a single oral hypoglycaemic agent or GLP-1 receptor agonist with glycated haemoglobin (HbA1c) concentration ≤10.0%
(≤86 mmol/mol) or no drug treatment with HbA1c concentration 7.0% to 10.0% (53-86 mmol/mol) and body mass index (BMI) ≥20 
| Study assessments
The primary endpoints were mean, SD, area under the curve (AUC) of glucose levels, and mean amplitude of glycaemic excursions (MAGE) derived from CGM data. 11 Other endpoints included fasting plasma glucose (FPG), insulin, C-peptide, glucagon, ketone bodies and non-esterified fatty acids. These endpoints were assessed in the full analysis set population (ie, participants who received at least 1 dose of luseoglifrozin with at least 1 point of efficacy data available).
Adverse events, using system organ class/preferred terms, and adverse drug reactions were summarized for the safety analysis set population (ie, participants who received at least 1 dose of luseoglifrozin with at least 1 point of safety data available).
| Statistical analysis
All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina). Baseline characteristics were compared using analysis of variance; a significance level of 15% (2-sided) was used to examine the heterogeneity of participant characteristics.
Repeated measures were assessed using mixed-design analysis of covariance. The unrestricted least significant difference method was applied to calculate the least squares mean and 95% confidence interval for changes in efficacy variables. Statistical significance was determined at the 5% level.
| RESULTS
Twenty-four Japanese people with T2D were recruited and randomly assigned into 3 groups: HC-HGI, HC-LGI and LC-HGI ( Figure S1 ).
These groups had similar baseline data (Table 1) , the duration of T2D in the LC-HGI group being slightly longer than in the HC-HGI and HC-LGI groups, but the difference was non-significant statistically.
Postprandial CGM values in the HC-HGI group were consistently higher than in the HC-LGI and LC-HGI groups before and after initiation of luseogliflozin treatment ( Figure S3 ). The HC-HGI group had higher peak blood glucose level (BG max ), AUC over 48 hours (AUC 0-48h ), and AUC 0-48h for glucose levels >10.0 mmol/L (high-range AUC 0-48h ); mean, SD and MAGE values were higher than in the HC-
LGI and LC-HGI groups (Table 2) , although the differences were not statistically significant. Importantly, luseogliflozin treatment significantly decreased the AUC and the mean of CGM data in all 3 groups. In the LC-HGI group, lower peak blood glucose level (BG min ) and area over the curve over 48 hour (AOC 0-48h ) for glucose levels <3.9 mmol/L (low-range Values are mean AE SD or n (%). Each item was compared among the 3 groups using analysis of variance. A significance of P < .15 (2-sided) was taken to indicate heterogeneity among the study groups.
Abbreviations: HOMA-β, homeostatic model assessment of β-cell function; HOMA-IR, homeostatic model assessment of insulin resistance; SUIT, secretory unit of islet in transplantation. All adverse events were mild in severity (Table S1 ). Among them, somnolence and urinary frequency were judged as adverse drug reactions; dermatitis was attributable to contact with fixed tape for CGM.
| DISCUSSION
In the present study, we found that luseogliflozin ameliorated hyperglycaemia in Japanese people with T2D receiving the 3 different test meals; however, ketone bodies were significantly increased by luseogliflozin in the LC-HGI group.
Luseogliflozin improved AUC 0-48h and mean of CGM data in all 3 groups, indicating that differences in carbohydrate content (55% vs 40% of TEC) and GI (white rice vs brown rice) did not affect the glucose-lowering effects. Luseogliflozin did not affect SD or MAGE values, confirming that SGLT2 inhibitors improve glycaemia without affecting glucose variability. This difference might be attributable to the fact that T2D in EastAsian populations, including Japanese populations, is characterized primarily by β-cell dysfunction rather than insulin resistance and subsequent hyperinsulinaemia. Indeed, many euglycaemic DKA cases in Japanese people with T2D receiving SGLT2 inhibitors occurred after withdrawal of sulphonylureas and/or insulin. 6 The present study showed that ketone bodies were significantly increased by luseogliflozin in the LC-HGI group, suggesting that SGLT2 inhibitors might trigger onset of euglycaemic DKA in individuals on a strict LC diet, with or without withdrawal of insulin and/or sulphonylureas.
Limitations of the present study include the lack of UGE measurements because of difficulties in 24-hour urine collection for outpatient participants; however, it is of interest to investigate the effects of carbohydrate intake adjustments on UGE before and after SGLT2 inhibitor treatment. UGE occurs when plasma glucose levels are higher than the renal threshold and SGLT2 inhibitor treatment lowers the threshold. 15 Because glucose profiles of the HC-LGI and LC-HGI groups were similar and lower than in the HC-HGI group before and after luseogliflozin treatment in the present study ( Figure S3 and Table 2 ), the UGEs in the HC-LGI and LC-HGI groups might well be similar and lower than in the HC-HGI group.
It is also uncertain whether 1 week is sufficient to stabilize the effects of dietary interventions in the absence or presence of luseogliflozin; it was previously shown that inter-day variability of daily glucose profiles over 3 consecutive days was minimal (mean of daily difference [MODD] 1.3-1.6 mmol/L) when food consumption was tightly controlled, 16 as it was in the present study (MODD 0.9-1.3 mmol/L); however, the effects during days 8 to 15 might partly be derived from the combined action of luseogliflozin and the dietary interventions.
In addition, the present study compared the effects of SGLT2 inhibitor use and carbohydrate intake adjustments for a short duration with a relatively small sample size; further investigations are necessary to address long-term safety and efficacy of SGLT2 inhibitors in individuals receiving meals of various carbohydrate content.
In conclusion, the present study shows the glucose-lowering effects of luseogliflozin, typical of SGLT2 inhibitors, with limited adverse events in Japanese people with T2D receiving meals consisting of 40% to 55% TEC with either an HGI or a LGI; however, our results suggest that the carbohydrate content of meals can play an important role in SGLT2 inhibitor-associated hepatic ketogenesis and onset of euglycaemic DKA.
